Study to Assess Efficacy of AZD1236 in Patients With Cystic Fibrosis

• Status: Withdrawn
• Trial end date: 2010-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effect of AZD1236 in patients with cystic fibrosis (CF) on inflammatory biomarkers in induced sputum, after a treatment period of 4 weeks.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca

Criteria

Inclusion Criteria:

• Provision of informed consent prior to any study specific procedures

• Have a clinical diagnosis of cystic fibrosis with an FEV1 >40% of predicted normal

• Be able to comply with induced sputum procedure

• post-menopausal surgically sterile female (total hysterectomy and /or bilateral total oophorectomy)

Exclusion Criteria:

• Concomitant diagnosis of significant pulmonary disease other than CF-related lung disease, including symptomatic asthma and allergic bronchopulmonary aspergillosis

• Treatment with any immunomodulatory agents within 8 weeks prior to Visit 2

• Known to be infected with Burkholderia cepacia